Naturally occurring translational models for development of cancer gene therapy

Gene Therapy and Molecular Biology

Volumn 10, Issue 1, 2006, Pages 31-40

  Modiano, Jaime F ^a,b,c,d   Breen, Matthew ^e,h   Lana, Susan E ^f   Ehrhart, Nicole ^f   Fosmire, Susan P ^b,c   Thomas, Rachael ^e   Jubala, Cristan M ^b,c   Lamerato Kozicki, Angela R ^b,c,i   Ehrhart, Eugene J ^f   Schaack, Jerome ^b,d   Duke, Richard C ^a,b,d   Cutter, Gary C ^g   Bellgrau, Donald ^a,b,d  

^a Apoplogic Inc   (United States)

^b UNIVERSITY OF COLORADO   (United States)

^c UNIVERSITY OF COLORADO   (United States)

^d UNIVERSITY OF COLORADO CANCER CENTER   (United States)

^e NORTH CAROLINA STATE UNIVERSITY   (United States)

^f Department of Environmental and Radiological Health Sciences   (United States)

^g UNIVERSITY OF ALABAMA AT BIRMINGHAM   (United States)

^h North Carolina State Univerisity   (United States)

ⁱ UNIVERSITY OF WISCONSIN MADISON   (United States)

Author keywords

Canine; Fas ligand; Gene therapy; Immunotherapy; Osteosarcoma

Indexed keywords

ANIMALIA; CANIS FAMILIARIS; MUS; RODENTIA;

EID: 34548435387     PISSN: 15299120     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (82)

1. Akatsuka T, Wada T, Kokai Y, Kawaguchi S, Isu K, Yamashiro K, Yamashita T, Sawada N, Yamawaki S Ishii S (2002) ErbB2 expression is correlated with increased survival of patients with osteosarcoma. Cancer 94, 1397-1404.
2. Al-Romaih K, Bayani J, Vorobyova J, Karaskova J, Park PC, Zielenska M Squire JA (2003) Chromosomal instability in osteosarcoma and its association with centrosome abnormalities. Cancer Genet Cytogenet 144, 91-99.
3. Anninga JK, van de Vijver MJ, Cleton-Jansen AM, Kristel PM, Taminiau AH, Nooij M, Egeler RM Hogendoorn PC (2004) Overexpression of the HER-2 oncogene does not play a role in high-grade osteosarcomas. Eur J Cancer 40, 963-970.
4. Antillon-Klussmann F, Garcia-Delgado M, Villa-Elizaga I Sierrasesumaga L (1995) Mutational activation of ras genes is absent in pediatric osteosarcoma. Cancer Genet Cytogenet 79, 49-53.
5. Araki N, Uchida A, Kimura T, Yoshikawa H, Aoki Y, Ueda T, Takai S, Miki T Ono K (1991) Involvement of the retinoblastoma gene in primary osteosarcomas and other bone and soft-tissue tumors. Clin Orthop 270, 271-277.
6. Barrios C, Castresana JS, Ruiz J Kreicbergs A (1993) Amplification of c-myc oncogene and absence of c-Ha-ras point mutation in human bone sarcoma. J Orthop Res 11, 556-563.
7. Batanian JR, Cavalli LR, Aldosari NM, Ma E, Sotelo-Avila C, Ramos MB, Rone JD, Thorpe CM Haddad BR (2002) Evaluation of paediatric osteosarcomas by classic cytogenetic and CGH analyses. Mol Pathol 55, 389-393.
8. Bayani J, Zielenska M, Pandita A, Al-Romaih K, Karaskova J, Harrison K, Bridge JA, Sorensen P, Thorner P Squire JA (2003) Spectral karyotyping identifies recurrent complex rearrangements of chromosomes 8, 17, and 20 in osteosarcomas. Genes Chromosomes Cancer 36, 7-16.
9. Benini S, Baldini N, Manara MC, Chano T, Serra M, Rizzi S, Lollini PL, Picci P Scotlandi K (1999) Redundancy of autocrine loops in human osteosarcoma cells. Int J Cancer 80, 581-588.
10. Bianco SR, Sun J, Fosmire SP, Hance K, Padilla ML, Ritt MG, Getzy DM, Duke RC, Withrow SJ, Lana S, Matthiesen DT, Dow SW, Bellgrau D, Cutter GR, Helfand SC Modiano JF (2003) Enhancing anti-melanoma immune responses through apoptosis. Cancer Gene Ther 10, 726-736.
11. Bielack SS, Kempf-Bielack B, Delling G, Exner GU, Rege S, Helmke K, Kotz R, Salzer-Kuntschik M, Werner M, Winkelmann W, Zoubek A, Jurgens H Winkler K (2002) Prognostic factors in high-grade osteosarcoma of the extremities or trunk: an analysis of 1,702 patients treated on neoadjuvant cooperative osteosarcoma study group protocols. J Clin Oncol 20, 776-790.
12. Burrow S, Andrulis IL, Pollak M Bell RS (1998) Expression of insulin-like growth factor receptor, IGF-1, and IGF-2 in primary and metastatic osteosarcoma. J Surg Oncol 69, 21-27.
13. Coltella N, Manara MC, Cerisano V, Trusolino L, Di Renzo MF, Scotlandi K Ferracini R (2003) Role of the MET/HGF receptor in proliferation and invasive behavior of osteosarcoma. Faseb J 17, 1162-1164.
14. Dernell WS, Straw RC Withrow SJ (2001). Tumors of the skeletal system. Small Animal Clinical Oncology. Withrow SJ and MacEwen EG. Philadelphia, Lippincott Williams & Wilkins,, 378-417.
15. Ehrhart N, Dernell WS, Hoffmann WE, Weigel RM, Powers BE Withrow SJ (1998) Prognostic importance of alkaline phosphatase activity in serum from dogs with appendicular osteosarcoma: 75 cases (1990-1996). J Am Vet Med Assoc 213, 1002-1006.
16. Entz-Werle N, Schneider A, Kalifa C, Voegeli AC, Tabone MD, Marec-Berard P, Marcellin L, Pacquement H, Terrier P, Boutard P, Meyer N, Gaub MP, Lutz P, Babin A Oudet P (2003) Genetic alterations in primary osteosarcoma from 54 children and adolescents by targeted allelotyping. Br J Cancer 88, 1925-1931.
17. Fellenberg J, Krauthoff A, Pollandt K, Delling G Parsch D (2004) Evaluation of the predictive value of Her-2/neu gene expression on osteosarcoma therapy in laser-microdissected paraffin-embedded tissue. Lab Invest 84, 113-121.
18. Ferracini R, Angelini P, Cagliero E, Linari A, Martano M, Wunder J Buracco P (2000) MET oncogene aberrant expression in canine osteosarcoma. J Orthop Res 18, 253-256.
19. Ferracini R, Di Renzo MF, Scotiandi K, Baldini N, Olivero M, Lollini P, Cremona O, Campanacci M Comoglio PM (1995) The Met/HGF receptor is over-expressed in human osteosarcomas and is activated by either a paracrine or an autocrine circuit. Oncogene 10, 739-749.
20. Ferrari S, Bertoni F, Zanella L, Setola E, Bacchini P, Alberghini M, Versari M Bacci G (2004) Evaluation of P-glycoprotein, HER-2/ErbB-2, p53, and Bcl-2 in primary tumor and metachronous lung metastases in patients with high-grade osteosarcoma. Cancer 100, 1936-1942.
21. Flint AF, U'Ren L, Legare ME, Withrow SJ, Dernell W Hanneman WH (2004) Overexpression of the erbB-2 protooncogene in canine osteosarcoma cell lines and tumors. Vet Pathol 41, 291-296.
22. Fox MH, Armstrong LW, Withrow SJ, Powers BE, LaRue SM, Straw RC Gillette EL (1990) Comparison of DNA aneuploidy of primary and metastatic spontaneous canine osteosarcomas. Cancer Res 50, 6176-6178.
23. Friedmann E, Salzberg Y, Weinberger A, Shaltiel S Gerst JE (2002) YOS9, the putative yeast homolog of a gene amplified in osteosarcomas, is involved in the endoplasmic reticulum (ER)-Golgi transport of GPI-anchored proteins. J Biol Chem 277, 35274-35281.
24. Gamberi G, Benassi MS, Bohling T, Ragazzini P, Molendini L, Sollazzo MR, Pompetti F, Merli M, Magagnoli G, Balladelli A Picci P (1998) C-myc and c-fos in human osteosarcoma: prognostic value of mRNA and protein expression. Oncology 55, 556-563.
25. Gisselsson D, Palsson E, Hoglund M, Domanski H, Mertens F, Pandis N, Sciot R, Dal Cin P, Bridge JA Mandahl N (2002) Differentially amplified chromosome 12 sequences in low-and high-grade osteosarcoma. Genes Chromosomes Cancer 33, 133-140.
26. Gorlick R, Anderson P, Andrulis I, Arndt C, Beardsley GP, Bernstein M, Bridge J, Cheung NK, Dome JS, Ebb D, Gardner T, Gebhardt M, Grier H, Hansen M, Healey J, Helman L, Hock J, Houghton J, Houghton P, Huvos A, Khanna C, Kieran M, Kleinerman E, Ladanyi M, Lau C, Malkin D, Marina N, Meltzer P, Meyers P, Schofield D, Schwartz C, Smith MA, Toretsky J, Tsokos M, Wexler L, Wigginton J, Withrow S, Schoenfeldt M Anderson B (2003) Biology of childhood osteogenic sarcoma and potential targets for therapeutic development: meeting summary. Clin Cancer Res 9, 5442-5453.
27. Gurney JG, Swensen AR Bulterys M (1999). Malignant Bone Tumors. Int Classif Childhood Cancer. NCI SEER Pediatric Monograph. Washington D.C., National Institutes of Health. 8, 1-12.
28. Hansen K Khanna C (2004) Spontaneous and genetically engineered animal models; use in preclinical cancer drug development. Eur J Cancer 40, 858-880.
29. Haydon RC, Deyrup A, Ishikawa A, Heck R, Jiang W, Zhou L, Feng T, King D, Cheng H, Breyer B, Peabody T, Simon MA, Montag AG He TC (2002) Cytoplasmic and/or nuclear accumulation of the beta-catenin protein is a frequent event in human osteosarcoma. Int J Cancer 102, 338-342.
30. Hohlbaum AM, Gregory MS, Ju ST Marshak-Rothstein A (2001) Fas ligand engagement of resident peritoneal macrophages in vivo induces apoptosis and the production of neutrophil chemotactic factors. J Immnnol 167, 6217-6224.
31. Ikeda S, Sumii H, Akiyama K, Watanabe S, Ito S, Inoue H, Takechi H, Tanabe G Oda T (1989) Amplification of both c-myc and c-raf-1 oncogenes in a human osteosarcoma. Jpn J Cancer Res 80, 6-9.
32. Jemal A, Murray T, Ward E, Samuels A, Tiwari RC, Ghafoor A, Feuer EJ Thun MJ (2005) Cancer statistics, 2005. CA Cancer J Clin 55, 10-30.
33. Kahler RA Westendorf JJ (2003) Lymphoid enhancer factor-1 and beta-catenin inhibit Runx2-dependent transcriptional activation of the osteocalcin promoter. J Biol Chem 278, 11937-11944.
34. Kanoe H, Nakayama T, Murakami H, Hosaka T, Yamamoto H, Nakashima Y, Tsuboyama T, Nakamura T, Sasaki MS Toguchida J (1998) Amplification of the CDK4 gene in sarcomas: tumor specificity and relationship with the RB gene mutation. Anticancer Res 18, 2317-2321.
35. Khanna C, Prehn J, Hayden D, Cassaday RD, Caylor J, Jacob S, Bose SM, Hong SH, Hewitt SM Helman LJ (2002) A randomized controlled trial of octreotide pamoate long-acting release and carboplatin versus carboplatin alone in dogs with naturally occurring osteosarcoma: evaluation of insulin-like growth factor suppression and chemotherapy. Clin Cancer Res 8, 2406-2412.
36. Khanna C, Wan X, Bose S, Cassaday R, Olomu O, Mendoza A, Yeung C, Gorlick R, Hewitt SM Helman LJ (2004) The membrane-cytoskeleton linker ezrin is necessary for osteosarcoma metastasis. Nat Med 10, 182-186.
37. Kochevar DT, Kochevar J Garrett L (1990) Low level amplification of c-sis and c-myc in a spontaneous osteosarcoma model. Cancer Lett 53, 213-222.
38. Ladanyi M, Park CK, Lewis R, Jhanwar SC, Healey JH Huvos AG (1993) Sporadic amplification of the MYC gene in human osteosarcomas. Diagn Mol Pathol 2, 163-167.
39. Lau CC, Harris CP, Lu XY, Perlaky L, Gogineni S, Chintagumpala M, Hicks J, Johnson ME, Davino NA, Huvos AG, Meyers PA, Healy JH, Gorlick R Rao PH (2004) Frequent amplification and rearrangement of chromosomal bands 6p12-p21 and 17p11.2 in osteosarcoma. Genes Chromosomes Cancer 39, 11-21.
40. Leonard P, Sharp T, Henderson S, Hewitt D, Pringle J, Sandison A, Goodship A, Whelan J Boshoff C (2003) Gene expression array profile of human osteosarcoma. Br J Cancer 89, 2284-2288.
41. Levine RA (2002) Overexpression of the sis oncogene in a canine osteosarcoma cell line. Vet Pathol 39, 411-412.
42. Levine RA Fleischli MA (2000) Inactivation of p53 and retinoblastoma family pathways in canine osteosarcoma cell lines. Vet Pathol 37, 54-61.
43. Levine RA, Forest T Smith C (2002) Tumor suppressor PTEN is mutated in canine osteosarcoma cell lines and tumors. Vet Pathol 39, 372-378.
44. Liao AT, McMahon M London C (2005) Characterization, expression and function of c-Met in canine spontaneous cancers. Vet Comp Oncol 3, 61-72.
45. Lindblad-Toh K, Wade CM, Mikkelsen TS, Karlsson EK, Jaffe DB, Kamal M, Clamp M, Chang JL, Kulbokas III EJ, Zody MC, Mauceli E, Xie X, Breen M, Wayne RK, Ostrander EA, Ponting CP, Galibert F, Smith DR, deJong PJ, Kirkness E, Alvarez P, Biagi T, Brockman W, Butler J, Chin C-W, Cook A, Cuff J, Daly MJ, DeCaprio D, Gnerre S, Grabherr M, Kleber M, Bardeleben C, Goodstadt L, Heger A, Hitte C, Kim L, Koepfli K-P, Parker HG, Pollinger J, Searle SMJ, Sutler NB, Thomas R, Webber C et al (2005) Genome sequence, comparative analysis and haplotype structure of the domestic dog. Nature, 438, 803-819.
46. Lonardo F, Ueda T, Huvos AG, Healey J Ladanyi M (1997) p53 and MDM2 alterations in osteosarcomas: correlation with clinicopathologic features and proliferative rate. Cancer 79, 1541-1547.
47. Lopez-Guerrero JA, Lopez-Gines C, Pellin A, Carda C Llombart-Bosch A (2004) Deregulation of the G1 to S-phase cell cycle checkpoint is involved in the pathogenesis of human osteosarcoma. Diagn Mol Pathol 13, 81-91.
48. MacEwen EG, Kutzke J, Carew J, Pastor J, Schmidt JA, Tsan R, Thamm DH Radinsky R (2003) c-Met tyrosine kinase receptor expression and function in human and canine osteosarcoma cells. Clin Exp Metastasis 20, 421-430.
49. Malawer MM, Link MP Donaldson SS (2001). Sarcomas of the soft tissue and bone. Cancer: Principles and Practice of Oncology. DeVita VT, Jr., Hellman S, et al, Philadelphia, Lippincott Williams & Wilkins. 2, 1891-1935.
50. Man TK, Lu XY, Jaeweon K, Perlaky L, Harris CP, Shah S, Ladanyi M, Gorlick R, Lau CC Rao PH (2004) Genome-wide array comparative genomic hybridization analysis reveals distinct amplifications in osteosarcoma. BMC Cancer 4, 45.
51. Mansky PJ, Liewehr DJ, Steinberg SM, Chrousos GP, Avila NA, Long L, Bernstein D, Mackall CL, Hawkins DS Helman LJ (2002) Treatment of metastatic osteosarcoma with the somatostatin analog OncoLar: significant reduction of insulin-like growth factor-1 serum levels. J Pediatr Hematol Oncol 24, 440-446.
52. Mealey KL, Barhoumi R, Rogers K Kochevar DT (1998) Doxorubicin induced expression of P-glycoprotein in a canine osteosarcoma cell line. Cancer Lett 126, 187-192.
53. Mendoza S, Konishi T, Dernell WS, Withrow SJ Miller CW (1998) Status of the p53, Rb and MDM2 genes in canine osteosarcoma. Anticancer Res 18, 4449-4453.
54. Miller CW, Aslo A, Won A, Tan M, Lampkin B Koeffler HP (1996) Alterations of the p53, Rb and MDM2 genes in osteosarcoma. J Cancer Res Clin Oncol 122, 559-565.
55. Modiano JF, Lamerato-Kozicki AR, Jubala CM, Coffey D, Borakove M, Schaack J Bellgrau D (2004) Fas ligand gene transfer for cancer therapy. Cancer Ther 2: 561-570.
56. Naka T, Iwamoto Y, Shinohara N, Ushijima M, Chuman H Tsuneyoshi M (1997) Expression of c-met proto-oncogene product (c-MET) in benign and malignant bone tumors. Mod Pathol 10, 832-838.
57. Nardeux PC, Daya-Grosjean L, Landin RM, Andeol Y Suarez HG (1987) A c-ras-Ki oncogene is activated, amplified and overexpressed in a human osteosarcoma cell line. Biochem Biophys Res Commun 146, 395-402.
58. Nielsen GP, Burns KL, Rosenberg AE Louis DN (1998) CDKN2A gene deletions and loss of p16 expression occur in osteosarcomas that lack RB alterations. Am J Pathol 153, 159-163.
59. Nielsen-Preiss SM, Silva SR Gillette JM (2003) Role of PTEN and Akt in the regulation of growth and apoptosis in human osteoblastic cells. J Cell Biochem 90, 964-975.
60. Oda Y, Naka T, Takeshita M, Iwamoto Y Tsuneyoshi M (2000) Comparison of histological changes and changes in nm23 and c-MET expression between primary and metastatic sites in osteosarcoma: a clinicopathologic and immunohistochemical study. Hum Pathol 31, 709-716.
61. Overholtzer M, Rao PH, Favis R, Lu XY, Elowitz MB, Barany F, Ladanyi M, Gorlick R Levine AJ (2003) The presence of p53 mutations in human osteosarcomas correlates with high levels of genomic instability. Proc Natl Acad Sci U S A 100, 11547-11552.
62. Ozaki T, Schaefer KL, Wai D, Buerger H, Flege S, Lindner N, Kevric M, Diallo R, Bankfalvi A, Brinkschmidt C, Juergens H, Winkelmann W, Dockhom-Dworniczak B, Bielack SS Poremba C (2002) Genetic imbalances revealed by comparative genomic hybridization in osteosarcomas. Int J Cancer 102, 355-365.
63. Ozisik YY, Meloni AM, Peier A, Altungoz O, Spanier SS, Zalupski MM, Leong SP Sandberg AA (1994) Cytogenetic findings in 19 malignant bone tumors. Cancer 74, 2268-2275.
64. Park YB, Park MJ, Kimura K, Shimizu K, Lee SH Yokota J (2002) Alterations in the INK4a/ARF locus and their effects on the growth of human osteosarcoma cell lines. Cancer Genet Cytogenet 133, 105-111.
65. Pellin A, Boix-Ferrero J, Carpio D, Lopez-Terrada D, Carda C, Navarro S, Peydro-Olaya A, Triche TJ Llombart-Bosch A (1997) Molecular alterations of the RB1, TP53, and MDM2 genes in primary and xenografted human osteosarcomas. Diagn Mol Pathol 6, 333-341.
66. Regardsoe EL, McMenamin MM, Charlton HM Wood MJ (2004) Local adenoviral expression of Fas ligand upregulates pro-inflammatory immune responses in the CNS. Gene Ther 11, 1462-1474.
67. Scholz RB, Kabisch H, Weber B, Roser K, Delling G Winkler K (1992) Studies of the RB1 gene and the p53 gene in human osteosarcomas. Pediatr Hematol Oncol 9, 125-137.
68. Scotlandi K, Baldini N, Oliviero M, Di Renzo MF, Martano M, Serra M, Manara MC, Comoglio PM Ferracini R (1996) Expression of Met/hepatocyte growth factor receptor gene and malignant behavior of musculoskeletal tumors. Am J Pathol 149, 1209-1219.
69. Setoguchi A, Okuda M, Nishida E, Yazawa M, Ishizaka T, Hong SH, Hisasue M, Nishimura R, Sasaki N, Yoshikawa Y, Masuda K, Ohno K Tsujimoto H (2001) Results of hyperamplification of centrosomes in naturally developing tumors of dogs. Am J Vet Res 62, 1134-1141.
70. Shimizu M, Fontana A, Takeda Y, Yoshimoto T, Tsubura A Matsuzawa A (2001) Fas/Apo-1 (CD95)-mediated apoptosis of neutrophils with Fas ligand (CD95L)-expressing tumors is crucial for induction of inflammation by neutrophilic polymorphonuclear leukocytes associated with antitumor immunity. Cell Immunol 207, 41-48.
71. Squire JA, Pei J, Marrano P, Beheshti B, Bayani J, Lim G, Moldovan L Zielenska M (2003) High-resolution mapping of amplifications and deletions in pediatric osteosarcoma by use of CGH analysis of cDNA microarrays. Genes Chromosomes Cancer 38, 215-225.
72. Sulzbacher I, Birner P, Trieb K, Traxler M, Lang S Chott A (2003) Expression of platelet-derived growth factor-AA is associated with tumor progression in osteosarcoma. Mod Pathol 16, 66-71.
73. Sztan M, Papai Z, Szendroi M, Looij M Olah E (1997) Allelic Losses from Chromosome 17 in Human Osteosarcomas. Pathol Oncol Res 3, 115-120.
74. Thomas R, Scott A, Langford C, Fosmire SP, Jubala CM, Lorentzen TD, Hitte C, Karlsson EK, Kirkness E, Ostrander EA, Galibert F, Lindblad-Toh K, Modiano JF Breen M (2005) Construction of a 2Mb resolution BAC-microarray for CGH analysis of canine tumors. Genome Res 15, 1831-1837.
75. van Dartel M Hulsebos TJ (2004) Amplification and overexpression of genes in 17p11.2 ∼ p12 in osteosarcoma. Cancer Genet Cytogenet 153, 77-80.
76. van Dartel M, Redeker S, Bras J, Kool M Hulsebos TJ (2004) Overexpression through amplification of genes in chromosome region 17p11.2 approximately p12 in high-grade osteosarcoma. Cancer Genet Cytogenet 152, 8-14.
77. Withrow SJ, Powers BE, Straw RC Wilkins RM (1991) Comparative aspects of osteosarcoma. Dog versus man. Clin Orthop 270
78. Withrow SJ, Thrall DE, Straw RC, Powers BE, Wrigley RH, Larue SM, Page RL, Richardson DC, Bissonette KW, Betts CW et al, (1993) Intra-arterial cisplatin with or without radiation in limb-sparing for canine osteosarcoma. Cancer 71, 2484-2490.
79. Worth LL, Lafleur EA, Jia SF Kleinerman ES (2002) Fas expression inversely correlates with metastatic potential in osteosarcoma cells. Oncol Rep 9, 823-827.
80. Yokoyama R, Schneider-Stock R, Radig K, Wex T Roessner A (1998) Clinicopathologic implications of MDM2, p53 and K-ras gene alterations in osteosarcomas: MDM2 amplification and p53 mutations found in progressive tumors. Pathol Res Pract 194, 615-621.
81. Zachos TA, Aiken SW, DiResta GR Healey JH (2001) Interstitial fluid pressure and blood flow in canine osteosarcoma and other tumors. Clin Orthop 385
82. Zielenska M, Marrano P, Thorner P, Pei J, Beheshti B, Ho M, Bayani J, Liu Y, Sun BC, Squire JA Hao XS (2004) High-resolution cDNA microarray CGH mapping of genomic imbalances in osteosarcoma using formalin-fixed paraffin-embedded tissue. Cytogenet Genome Res 107, 77-82.